Advances in Magnetic Resonance Imaging Contrast Agents for Biomarker Detection.
Advances in Magnetic Resonance Imaging Contrast Agents for Biomarker Detection.
复制标题
DOI：
10.1146/annurev-anchem-071015-041514
复制
发表时间：
2016-06-12
期刊：
影响因子：
--
通讯作者：
Pagel MD
中科院分区：
文献类型：
--
作者：
Sinharay S;Pagel MD
磁共振成像（MRI）造影剂的最新进展为通过分子成像进行生物标志物检测提供了新的能力。基于T2交换机制的MRI造影剂最近扩展了用于分子成像的试剂的设备。与T1和T2* 试剂相比，T2交换试剂具有较慢的化学交换速率，这提高了设计这些MRI造影剂的能力，这些造影剂具有更高的检测预期生物标志物的特异性。通过化学交换饱和转移（CEST）检测的MRI造影剂具有更慢的化学交换速率。另一类新兴的MRI造影剂使用超极化13C以突出的灵敏度检测试剂。这些超极化13C试剂可用于跟踪代谢和监测组织微环境的特征。总之，这些不同的MRI造影剂为开发用于生物标志物检测的分子成像提供了极好的机会。
Recent advances in magnetic resonance imaging (MRI) contrast agents have provided new capabilities for biomarker detection through molecular imaging. MRI contrast agents based on the T2 exchange mechanism have more recently expanded the armamentarium of agents for molecular imaging. Compared with T1 and T2* agents, T2 exchange agents have a slower chemical exchange rate, which improves the ability to design these MRI contrast agents with greater specificity for detecting the intended biomarker. MRI contrast agents that are detected through chemical exchange saturation transfer (CEST) have even slower chemical exchange rates. Another emerging class of MRI contrast agents uses hyperpolarized 13C to detect the agent with outstanding sensitivity. These hyperpolarized 13C agents can be used to track metabolism and monitor characteristics of the tissue microenvironment. Together, these various MRI contrast agents provide excellent opportunities to develop molecular imaging for biomarker detection.